SynthesisBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026
Incidence and Risk Factors of Treatment-Emergent Eczematous Reactions in Patients with Psoriasis Treated with Biologics: A Systematic Review and Meta-Analysis.
Synthesis in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
BACKGROUND AND
objectiveTreatment-emergent eczematous reactions have been reported in patients with psoriasis receiving biologic therapies, but their pooled incidence and associated factors remain unclear. We aimed to estimate the incidence and associated factors for treatment-emergent eczematous reactions in biologic-treated psoriasis patients.
methodsWe searched PubMed, EMBASE, and Web of Science (to Jan 2026) for studies reporting new-onset or exacerbated eczema in psoriasis patients treated with tumor necrosis factor (TNF), interleukin-17 (IL-17), interleukin-12/23 (IL-12/23), or IL-23 inhibitors. Two eligible studies of the oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib were analyzed separately as an exploratory subgroup. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, data were synthesized using a random-effects model with Freeman-Tukey double arcsine transformation. The primary outcome was the pooled incidence of treatment-emergent eczematous reactions. Secondary analyses examined differences according to biologic class, dosage, and demographic characteristics.
resultsAnalysis of 26 publications (34,511 exposures) showed a 2.17% overall incidence (95% CI 1.57-2.85). Pooled incidence differed by class (p < 0.001): IL-17 inhibitors had the highest incidence (3.47%; 95% CI 2.34-4.77), followed by IL-12/23 (2.15%; 95% CI 0.04-6.59) and TNF inhibitors (1.02%; 95% CI 0.83-1.23), and IL-23 inhibitors had the lowest (0.09%; 95% CI 0.00-0.71). Within the IL-17 class, pooled incidence was higher with secukinumab (5.3%; 95% CI 2.95-8.2) than with ixekizumab (1.51%; 95% CI 0.41-3.1). High-dose regimens were associated with a higher pooled incidence than low-dose regimens (7.65% vs 3.36%; p = 0.03). Incidence was higher in studies conducted in East Asian populations (~ 6%) than in Western populations (~ 1%). A history of atopic dermatitis showed the strongest patient-level association with treatment-emergent eczematous reactions (hazard ratio, 12.40; 95% CI 6.97-22.06).
conclusionsEczematous reactions in biologic-treated psoriasis were associated with biologic class, dose, and study population, with the highest incidences for IL-17 inhibitors, high-dose regimens, and studies of East Asian populations.
Identifiers
42886333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.